Gubra submits clinical trial application (CTA) for first-in-human amylin trial
Gubra announces that a clinical trial application (CTA) for the anti-obesity amylin project has been submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The clinical trial is expected to receive approval from the MHRA later…